Althea Group Holdings has announced the launch of CBD100 – a highly concentrated, full-spectrum CBD product – which should substantially increase Althea's patient numbers.
After announcing it had prescribed medicinal cannabis products to a total of 2,705 patients, Althea Group Holdings (ASX: AGH) has now announced the launch of CBD100, a highly concentrated, full-spectrum cannabidiol (CBD) oral oil product.
The product also contains small traces of terpenes, flavonoids, and other cannabinoids, with less than 1mg per ml of tetrahydrocannabinol (THC), the compound in cannabis which gets users high. The company states that CBD100 will be Althea's most highly concentrated CBD medicinal cannabis product.
Althea states that CBD100 brings a competitive advantage over competitors who typically use CBD devout of any other cannabinoids – often called isolate CBD – in that CBD100 contains a host of cannabinoids such as CBG, THCV and others in order to attain the Entourage Effect. Researchers believe that the Entourage Effect yields more therapeutic value for consumers.
According to Cannvalate, one of Australia's largest network of prescribing clinics,'CBD only' products account for approximately 30% of their total prescriptions, showing a promising market for Althea's new cannabinoid medicine. The potential marketability for CBD100 is backed up by Cannabis Access Clinics, who state that Althea's CBD100 has the potential to address a significant proportion of their clientele.
Dr Sud Agarwal, CEO of Cannvalate stated that "Althea CBD100 contains minimal THC (<0.08%) and so should meet the needs of Cannvalate's network of 1000+ doctors, especially those who want a pure CBD product, those who are concerned about driving impairment and for certain pediatric patient populations."
CBD100 is also Good Manufacturing Practice (GMP) certified, which ensures that Althea's products are of high quality.
Launching Althea CBD100 fills an important gap in our existing product portfolio.Josh Fegan, Althea Group Holdings CEO
Fegan went on to say that "based on our extensive market research including discussions with various clinics, doctors and patients, we believe that Althea CBD100 will be well received in the marketplace. We are very proud of the fact Althea CBD100 is formulated and manufactured in Australia under GMP."
The news of CBD100 follows Althea's recent announcement that the company is on track to reach 4,000 patient prescriptions in Australia by the end of 2019, with medicinal products prescribed by 348 Healthcare Professionals.
On top of this, Althea continues to make significant progress in the United Kingdom. This week, the Company received further Home Office import licences for supply of Althea's medicinal cannabis products. The Company has already forged an industry-leading position in the UK, an emerging medicinal cannabis market with significant potential.
To learn more about Althea Group Holdings, visit their company HQ here.
Get the Latest Marijuana News &
Content in your Inbox!
All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors